Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A known ✓ | Q03164 | 1/20 | 0.52 |
| ▸ | MLNR known ✓ | O43193 | 1/20 | 0.46 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 14/20 | 0.77 |
| ▸ | PGR | P06401 | 6/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.77 |
| ▸ | AR | P10275 | 4/20 | 0.77 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.77 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.77 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.77 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | CNR1 | P21554 | 1/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11903930 | 0.97 | NR3C1 (0.76) | NR3C1PGRCYP3A4ARADORA3 | |
| SCHEMBL3365954 | 0.97 | NR3C1 (0.76) | NR3C1PGRCYP3A4ARADORA3 | |
| SCHEMBL4284 | 0.96 | NR3C1 (0.83) | NR3C1PGRCYP3A4ARADORA3 | |
| Alcohol SCHEMBL9363106 | 0.94 | NR3C1 (0.81) | NR3C1PGRCYP3A4ARADORA3 | |
| Acetone SCHEMBL14645259 | 0.94 | NR3C1 (0.81) | NR3C1PGRCYP3A4ARADORA3 | |
| Fluticasone Propionate SCHEMBL1692230 | 0.92 | NR3C1 (0.90) | NR3C1PGRCYP3A4ARADORA3 | |
| Fluticasone Propionate SCHEMBL3369738 | 0.92 | NR3C1 (0.86) | NR3C1PGRCYP3A4ARADORA3 | |
| SCHEMBL16474135 | 0.92 | NR3C1 (0.81) | NR3C1PGRCYP3A4ARADORA3 | |
| Norflurane SCHEMBL9366922 | 0.91 | NR3C1 (0.76) | NR3C1PGRCYP3A4ARADORA3 | |
| SCHEMBL2100405 | 0.91 | NR3C1 (0.78) | NR3C1PGRCYP3A4ARADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3154980-B1 | TETRAHYDROTRIAZOLOPYRIMIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES | CHIESI FARM SPA (IT) | 2021-08-04 | — | — | EP | disclosed |
| EP-3464273-B9 | IMIDAZOLONE COMPOUNDS AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | CHIESI FARM SPA (IT) | 2020-10-21 | — | — | EP | disclosed |
| EP-3390405-B1 | NOVEL TETRAHYDROTRIAZOLOPYRIMIDINE DERIVATIVES AS NHE INHIBITORS | CHIESI FARM SPA (IT) | 2020-07-15 | — | — | EP | disclosed |
| EP-3464273-B1 | IMIDAZOLONE COMPOUNDS AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | CHIESI FARM SPA (IT) | 2020-04-08 | — | — | EP | disclosed |
| EP-3464269-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF A HNE RELATED DISEASE | CHIESI FARM SPA (IT) | 2020-04-01 | — | — | EP | disclosed |
| EP-3464268-B1 | NOVEL COMPOUNDS | CHIESI FARM SPA (IT) | 2020-03-11 | — | — | EP | disclosed |
| EP-3464268-A1 | NOVEL COMPOUNDS | Chiesi Farmaceutici S.p.A. (IT) | 2019-04-10 | — | — | EP | disclosed |
| EP-3464273-A1 | IMIDAZOLONE COMPOUNDS AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2019-04-10 | — | — | EP | disclosed |
| EP-3464269-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF A DISEASE IN WHICH HNE IS IMPLICATED | Chiesi Farmaceutici S.p.A. (IT) | 2019-04-10 | — | — | EP | disclosed |
| EP-3233833-B1 | NOVEL COMPOUNDS | CHIESI FARM SPA (IT) | 2019-02-20 | — | — | EP | disclosed |
| US-20120041043-A1 | Sulfonamide Compounds for the Treatment of Respiratory Disorders | PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| EP-2379507-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISORDERS | Pulmagen Therapeutics (Inflammation) Limited (GB) | 2011-10-26 | — | — | EP | disclosed |
| CN-102170864-A | Treatment of Respiratory Diseases | ARGENTA DISCOVERY LTD | 2011-08-31 | — | — | CN | disclosed |
| WO-2011098799-A2 | RESPIRATORY DISEASE TREATMENT | PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) | 2011-08-18 | — | — | WO | disclosed |
| WO-2011098801-A1 | INFLAMMATORY DISEASE TREATMENT | PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) | 2011-08-18 | — | — | WO | disclosed |
| WO-2011098746-A1 | CRYSTALLINE ACID ADDITION SALTS OF ( 5R) -ENANTI0MER OF PIOGLITAZONE | PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) | 2011-08-18 | — | — | WO | disclosed |
| US-20110053986-A1 | RESPIRATORY DISEASE TREATMENT | PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
| WO-2010150014-A1 | 5R- 5 -DEUTERATED GLITAZONES FOR RESPIRATORY DISEASE TREATMENT | PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) | 2010-12-29 | — | — | WO | disclosed |
| WO-2010076553-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISORDERS | DR. REDDY'S LABORATORIES LTD (IN) | 2010-07-08 | — | — | WO | disclosed |
| WO-2009019598-A2 | INHALATION THERAPY FOR RESPIRATORY DISORDERS | DR. REDDY'S LABORATORIES LTD. (US) | 2009-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041043-A1 | Sulfonamide Compounds for the Treatment of Respiratory Disorders | PPARD, PPARA, PPARG | MEN1 4777/4885KMT2A 2750/4885MLNR 693/4885 |
| US-20110053986-A1 | RESPIRATORY DISEASE TREATMENT | IL5, PPARD, PPARG | MEN1 4424/4885KMT2A 1955/4885MLNR 1262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.